Pneumology - Original Articles

Clinical spectrum and profile of interstitial lung disease: an ambispective study from a tertiary center in North India

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 2 April 2026
158
Views
109
Downloads

Authors

Interstitial lung diseases (ILDs) comprise a heterogeneous group of disorders characterized by varying degrees of inflammation and fibrosis, necessitating precise epidemiological characterization. This ambispective observational study evaluated the clinical spectrum and diagnostic distribution of 1201 patients at a tertiary center in North India, utilizing a multidisciplinary discussion (MDD) framework for final diagnostic consensus. The mean age of the cohort was 52.7 (±13.04) years, with a female predominance of 55.6%. Idiopathic interstitial pneumonia (IIP) was the most prevalent diagnosis (48.8%), followed by connective tissue disease-associated ILD (CTD-ILD; 19.8%) and hypersensitivity pneumonitis (14.6%). Within the IIP subgroup, idiopathic pulmonary fibrosis predominated (49.7%), followed by nonspecific interstitial pneumonia (39.2%). Statistical analysis identified tobacco use as a significant driver for IIP phenotypes (odds ratio: 3.36; 95% confidence interval: 2.37-4.75; p<0.01). Physiological assessment revealed a restrictive ventilatory defect in 83.9% of the cohort. Patients with sarcoidosis (13.4%) exhibited significantly higher functional reserve (mean forced vital capacity %: 74.1±17.9%) compared to more fibrotic subtypes (p<0.01), and demonstrated superior exercise capacity (mean 6-minute walk distance: 392.4±85.6 m vs. 347.7±90.1 m in CTD-ILD; p<0.01). These findings establish that fibrotic IIPs constitute the primary disease burden in North India, highlighting the clinical necessity of standardized, MDD-based pathways to ensure accurate phenotype differentiation and timely initiation of targeted therapies in a region characterized by complex environmental triggers.

Downloads

Download data is not yet available.

Citations

Raghu G, Mehta S. Interstitial lung disease (ILD) in India: insights and lessons from the prospective, landmark ILD-India registry. Lung India 2016;33:589-91.
Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-48.
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015;46:976-87.
Dhooria S, Agarwal R, Sehgal IS, et al. Spectrum of interstitial lung diseases at a tertiary center in a developing country: a study of 803 subjects. PLoS One 2018;13:e0191938.
Singh S, Collins BF, Sharma BB, et al. Interstitial lung disease in India results of a prospective registry. Am J Respir Crit Care Med 2017;195:801-13.
López-Campos JL, Rodríguez-Becerra E, The Neumosur Task Group of the Registry of Interstitial Lung Diseases (RENIA). Incidence of interstitial lung diseases in the south of Spain 1998-2000: the RENIA study. Eur J Epidemiol 2004;19:155-61.
Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150:967-72.
Tinelli C, De Silvestri A, Richeldi L, Oggionni T. The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. Sarcoidosis Vasc Diffus Lung Dis 2005;22:S4-8.
Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece . Respir Med 2009;103:1122-9.
Hyldgaard C, Hilberg O, Muller A, Bendstrup E. A cohort study of interstitial lung diseases in central Denmark. Respir Med 2014;108:793-9.
Schweisfurth H, Kieslich C, Satake N, et al. How are interstitial lung diseases diagnosed in Germany? Results of the scientific registry for the exploration of interstitial lung diseases ("Fibrosis registry") of the WATL. Pneumologie 2003;57:373-82. [Article in German].
Kumar R, Gupta N, Goel N. Spectrum of interstitial lung disease at a tertiary care centre in India. Pneumonol Alergol Pol 2014;82:218-26.

Ethics Approval

All India Institute of Medical Sciences, New Delhi, Institutional Ethics Committee issued approval IECPG-586/24.10.2019. Approved - Approval number: IECPG-586/24.10.2019.

How to Cite



“Clinical Spectrum and Profile of Interstitial Lung Disease: An Ambispective Study from a Tertiary Center in North India”. 2026. Monaldi Archives for Chest Disease, April. https://doi.org/10.4081/monaldi.2026.3644.